Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Period	Debt/Equity
2015-12-31	7.26
2016-12-31	12.78
2017-12-31	5.39
2018-12-31	10.86
2019-12-31	30.79
2020-12-31	57.19
2021-12-31	-275.81
2022-12-31	-36.74
2023-12-31	-26.84
2024-12-31	-20.99

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BHC	$5.32	+1.14%	0.89M
3
4
5

Bausch Health Companies Inc. (BHC) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Bausch Health Companies Inc. Data in Excel

More BHC Financial Data